TriPRIL CAR T Cells in Multiple Myeloma

This study tests a new type of CAR T-cell therapy called TriPRIL — a treatment that modifies a patient's own immune cells to attack multiple myeloma cancer cells — in patients whose cancer has come back or stopped responding to prior treatment. **You may be eligible if...** - You are 18 or older with relapsed or refractory multiple myeloma confirmed by biopsy - You have measurable disease (detectable by serum M-protein, urine M-protein, or free light chains) - Your physical health is adequate (ECOG performance score 0–2) - Your life expectancy is at least 12 weeks - You have received prior standard therapies and they are no longer working **You may NOT be eligible if...** - You have active uncontrolled infections - You have significant heart, lung, liver, or kidney problems - You are pregnant or breastfeeding - You have had prior CAR T-cell therapy that targeted certain markers - You have active autoimmune disease or are on immunosuppressive therapy Talk to your doctor to see if this trial is right for you.